Dr. Agarwal on Remaining Challenges in mCSPC
In Partnership With:
Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.
Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses remaining challenges in metastatic castration-sensitive prostate cancer (mCSPC).
The shift toward utilizing novel hormonal therapies in the frontline setting for men with mCSPC has resulted in a dramatic improvement in overall survival, without hindering quality of life, explains Agarwal. Some of these therapies include apalutamide (Erleada), enzalutamide (Xtandi), and abiraterone acetate (Zytiga), Agarwal says.
However, patients with mCSPC who progress on these therapies represent a challenging population to treat with additional therapy. As such, future research efforts should aim to identify new targets, as well as therapies with novel mechanisms of action, to meet the need of these patients, says Agarwal. Additionally, patients with mCSPCshould be treated as early as possible, Agarwal concludes.
